Tumor Microenvironment: Bone Marrow-mesenchymal Stem Cells As Key Players
Overview
Biophysics
Affiliations
Tumor progression is a multistep phenomenon in which tumor-associated stromal cells perform an intricate cross-talk with tumor cells, supplying appropriate signals that may promote tumor aggressiveness. Among several cell types that constitute the tumor stroma, the discovery that bone marrow-derived mesenchymal stem cells (BM-MSC) have a strong tropism for tumors has achieved notoriety in recent years. Not only are the BM-MSC recruited, but they can also engraft at tumor sites and transdifferentiate into cells such as activated fibroblasts, perivascular cells and macrophages, which will perform a key role in tumor progression. Whether the BM-MSC and their derived cells promote or suppress the tumor progression is a controversial issue. Recently, it has been proposed that proinflammatory stimuli can be decisive in driving BM-MSC polarization into cells with either tumor-supportive or tumor-repressive phenotypes (MSC1/MSC2). These considerations are extremely important both to an understanding of tumor biology and to the putative use of BM-MSC as "magic bullets" against tumors. In this review, we discuss the role of BM-MSC in many steps in tumor progression, focusing on the factors that attract BM-MSC to tumors, BM-MSC differentiation ability, the role of BM-MSC in tumor support or inhibition, the immunomodulation promoted by BM-MSC and metastatic niche formation by these cells.
Mesenchymal stem cell transplantation plays a role in relieving cancer pain.
Zhang W, Chen D Front Pharmacol. 2024; 15:1483716.
PMID: 39679363 PMC: 11637888. DOI: 10.3389/fphar.2024.1483716.
Baquerizo H, Munoz S, Sherman L, Petryna A, Fitzhugh V, Fraidenraich D J Community Med Public Health. 2024; 8.
PMID: 39628958 PMC: 11614190. DOI: 10.29011/2577-2228.100409.
Masciale V, Banchelli F, Grisendi G, Samarelli A, Raineri G, Rossi T J Biol Chem. 2024; 300(12):107994.
PMID: 39547513 PMC: 11714729. DOI: 10.1016/j.jbc.2024.107994.
Giorello M, Borzone F, Mora M, Padin M, Wernicke A, Labovsky V Cancer Biomark. 2024; 41(2):115-132.
PMID: 39240628 PMC: 11492045. DOI: 10.3233/CBM-230523.
Kacaroglu D, Yaylaci S, Gurbuz N Cancer Med. 2024; 13(2):e6964.
PMID: 38379331 PMC: 10831913. DOI: 10.1002/cam4.6964.